Q2
CRDL — Q2 2026 Financial Report Analysis
Cardiol Therapeutics' Q2 2026 net loss narrowed to C$6.1M on non-cash warrant and FX gains while spending on its Phase III MAVERIC trial doubled; enrollment hit 110 patients, but the readout has slipped to mid-2027 and cash is guided into Q1 2028.